Skip to main content

Table 2 Data in patients with and without hepatic steatosis

From: Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

  Hepatic steatosis Hepatic steatosis p value
  Yes No  
  n = 35 n = 25  
Age at biopsy (yrs) 39.0 ± 8.9 40.0 ± 7.2 ns
Age at HIV diagnosis (yrs) 32.9 ± 8.9 34.0 ± 6.8 ns
Male 32 (91%) 22 (88%) ns
ethnicity 14 (40%) 9 (36%) ns
Weight (kg) 74.2 ± 9.2 69.7 ± 10.8 0.74
Weight > 75 kg 17 (48%) 7 (28%) ns
Diabetes mellitus 2 (6%) 1 (4%) ns
Alcohol 11 (31%) 7 (28%) ns
Antiretroviral therapy    
No therapy 10 (28%) 7 (28%) ns
NRTI 7 (20%) 3 (12%) ns
Duration (mths) 22.3 ± 18.8 21.7 ± 12.4 ns
HAART only 9 (26%) 13 (52%) 0.037
Duration (mths) 30.4 ± 27.3 29.5 ± 27.1 ns
Sequential 9 (26%) 2 (8%) 0.08
Duration (mths) 92.8 ± 37.2 106.0 ns
Received PI 13 (37%) 8 (32%) ns
Received NNRTI 14 (40%) 10 (40%) ns
Received stavudine 12 (34%) 5 (20%) ns
Received didanosine 8 (23%) 5 (20%) ns
Received zidovudine 21 (60%) 12 (48%) ns
Time from HIV diagnosis to HAART (mths) 47.4 + 38.7 40.4 + 50.9 ns
CD4 count (/mm3) 410 (110–1100) 490 (100–1200) ns
HIV VL (copies/ml) UD (UD-210955) 70 (UD-121843) ns
HCV VL (IU/ml) 441309 (2716–769231) 1286755 (29451–14975540) ns
Non 1 genotype 6/21 (28%) 6/21 (28%) ns
Cholestrol 4.3 ± 1.2 4.1 ± 1.08 ns
HDL 1.1 ± 0.5 1.1 ± 0.3 ns
Triglyceride 2.2 ± 2.0 1.5 ± 0.6 ns
Cholestrol/HDL ratio 4.8 ± 2.2 3.8 ± 1.0 ns
Fasting blood glucose 6.1 + 6.4 5.1 ± 0.9 ns
ALT (IU/L) 131 + 149.8 104 ± 74.6 ns
Fibrosis stage 3.0 ± 1.9 2.5 ± 1.7 ns
NI grade 3.7 ± 1.9 3.7 + 1.7 ns
Cirrhosis 12 (34%) 3 (12%) 0.049
  1. Normal range for lab values: ALT <40 iu/L, Bilirubin <17 umol/L, Alkaline phosphates 30–130 iu/L, Albumin 35–41 g/L, Cholestrol <5 mmol/L, triglycerides <2.30 mmol/L, HDL cholesterol >1.00 mmol/L, Cholestrol/HDL <5.00 mmol/L, fasting blood glucose 3–5.5 mmol/L
  2. HDL: high density lipoprotein
  3. UD: undetectable
  4. Data on lipids unavailable in 10 patients